Preview

User

Not a user? Register with this site Forgot your password?

Osteoporosis and Bone Diseases

Advanced search

PLEIOTROPIC EFFECTS OF THE BONE METABOLISM MODULATOR - STRONTIUM RANELATE IN TREATMENT OF WOMEN WITH THE POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION.

https://doi.org/10.14341/osteo201013-5

Abstract

The trial was aimed at studying the effects of the modulator of bone metabolism - strontium ranelate on the parameters of cardiovascular remodeling in women with postmenopausal osteoporosis (OP) and arterial hypertension (AH). This effect includes the results of study of strontium ranelate in 48 women with postmenopausal osteoporosis AH 1-2 degrees and moderate or high cardiovascular risk. During 36 weeks 25 patients, in addition to antihypertensive therapy and calcium supplementation received strontium ranelate (Bivalos) 2 g / day. Bone mineral density (BMD) was evaluated by dual energy X-ray absorptiometry. The effect of strontium ranelate treatment on the thickness of the intima-media of the carotid artery (IMT) by the method of duplex scanning on structural and functional parameters of the heart by echocardiography also evaluated. Adding of strontium ranelate to the antihypertensive treatment and calcium supplementation in women with postmenopausal OP and AH has a positive effect on central hemodynamics, cardiovascular remodeling and diastolic filling.

References

1. Маличенко С.Б. Постменопаузальный симптомокомплекс: роль кальция и витамина D в развитии, профилактике и лечении клинических проявлений эстрогенного дефицита // Consilium Medicum. - 2005. - Том 7, №8. - С. 1464-1475.

2. Насонов Е..Л. Остеопороз и заболевания сердечно-сосудистой системы. // Кардиология. - 2002. - №3. - С. 80-82.

3. Руководство по остеопорозу / Под редакцией доктора медицинских наук, профессора Л.И. Беневоленской. - М.: БИНОМ, 2003. -523 с.

4. Brennan Т., Rybchyn MS, Conigrave AD, et al. Strontium ranelate effect on proliferation and OPG expression in osteoblasts // Calcif Tissue Int. - 2006. - Vol. 78. - P.356.

5. Kenchaiah S., Pfeffer M. Cardiac remodeling in systemic hypertension // Med Clin North Am. - 2004. - Vol 88 (1). - P. 115-130.

6. Legedz L., Rial M.O, Lantelme P. Markers of cardiovascular remodeling in hypertension // Arch Mai Coeur Vaiss. - 2003. - Vol. 96 (7-8). - P. 729-733.

7. Reginster J., Seeman E., De Vernejoul M. Et al Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) Study // J. Clin.Endocrinol. Metab. - 2005. - Vol. 90. - P. 2816-2822.

8. Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors // J Bone Miner Res. -2006. - Vol.21. - P.536-542.

9. Safar M.E., Smulyan H. Hypertension in women // Am J Hypertens. - 2004. - Vol. 17 (1). - P. 82-87.


Review

For citations:

Khozyainova N.Yu., Tsareva V.M., Bezaltynnykh M.S., Bruk T.V., Hozyainova N.Y., Tsareva V.M., Bezaltynnih M.S., Brak T.V. PLEIOTROPIC EFFECTS OF THE BONE METABOLISM MODULATOR - STRONTIUM RANELATE IN TREATMENT OF WOMEN WITH THE POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION. Osteoporosis and Bone Diseases. 2010;13(1):3-5. https://doi.org/10.14341/osteo201013-5

Views: 413


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)

11, Dmitriya Ul'yanova str., Moscow, Russian Federation, 117036

Processing of personal data
supported by NEICON (Elpub lab)